One Health - BHP
·Aug 18, 2026
Source: BHP
Read the original article This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
This article is an excerpt. To read the full content, visit the original source. BHP
Reactions
Related articles
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
Oncodaily·
0 comments
No comments yet. Be the first to share your thoughts!